{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:51:29Z","timestamp":1760889089740,"version":"build-2065373602"},"reference-count":117,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jfo.2015.09.006","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T07:50:25Z","timestamp":1446537025000},"page":"996-1008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Traitements actuels de la n\u00e9ovascularisation corn\u00e9enne"],"prefix":"10.1016","volume":"38","author":[{"given":"Y.","family":"Benayoun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Petellat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Dost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Dallaudi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.-Y.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-L.","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2015.09.006_bib0590","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: an epidemiologic review","volume":"43","author":"Lee","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0595","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00003226-199811000-00008","article-title":"Angiogenesis in corneal diseases: histopathologic evaluation of 254\u00a0human corneal buttons with neovascularization","volume":"17","author":"Cursiefen","year":"1998","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib0600","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3181\/00379727-74-17822","article-title":"Inhibition of vascularization of the rabbit cornea by local application of cortisone","volume":"74","author":"Jones","year":"1950","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.jfo.2015.09.006_bib0605","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00417-005-0036-1","article-title":"Inhibitory effect of triamcinolone acetonide on corneal neovascularization","volume":"244","author":"Murata","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0610","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/ICO.0b013e3181605ff9","article-title":"Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline","volume":"27","author":"Aydin","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib0615","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1126\/science.2467380","article-title":"Control of angiogenesis with synthetic heparin substitutes","volume":"243","author":"Folkman","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jfo.2015.09.006_bib0620","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1210\/endo-119-4-1768","article-title":"A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution","volume":"119","author":"Ingber","year":"1986","journal-title":"Endocrinology"},{"key":"10.1016\/j.jfo.2015.09.006_bib0625","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jcp.1041550315","article-title":"Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis","volume":"155","author":"Blei","year":"1993","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0630","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00000658-198709000-00016","article-title":"Angiostatic steroids. Method of discovery and mechanism of action","volume":"206","author":"Folkman","year":"1987","journal-title":"Ann Surg"},{"key":"10.1016\/j.jfo.2015.09.006_bib0635","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/archopht.1983.01040010640024","article-title":"Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization","volume":"101","author":"Phillips","year":"1983","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0640","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02713688508999984","article-title":"Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea","volume":"4","author":"Mahoney","year":"1985","journal-title":"Curr Eye Res"},{"year":"1991","series-title":"Corneal angiogenesis: a comprehensive critical review","author":"Klintworth","key":"10.1016\/j.jfo.2015.09.006_bib0645"},{"key":"10.1016\/j.jfo.2015.09.006_bib0650","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0655","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.exer.2004.04.008","article-title":"Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization","volume":"79","author":"Castro","year":"2004","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jfo.2015.09.006_bib0660","first-page":"1306","article-title":"Antiangiogenic and antitumor activities of cyclooxygenase-2\u00a0inhibitors","volume":"60","author":"Masferrer","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.jfo.2015.09.006_bib0665","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0002-9394(14)77376-3","article-title":"Flurbiprofen in the treatment of corneal neovascularization induced by contact lenses","volume":"93","author":"Duffin","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0670","first-page":"293","article-title":"Indomethacin vs. dexamethasone in the suppression of corneal neovascularization","volume":"18","author":"Harvey","year":"1983","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0675","first-page":"2485","article-title":"Loss and restoration of immune privilege in eyes with corneal neovascularization","volume":"37","author":"Dana","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2015.09.006_bib0680","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1167\/iovs.02-0346","article-title":"Topical nepafenac inhibits ocular neovascularization","volume":"44","author":"Takahashi","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2015.09.006_bib0685","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.phrs.2011.06.013","article-title":"The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease","volume":"64","author":"Federici","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jfo.2015.09.006_bib0690","first-page":"18","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies","volume":"93","author":"Del Rosso","year":"2014","journal-title":"Cutis"},{"key":"10.1016\/j.jfo.2015.09.006_bib0695","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1167\/iovs.12-10323","article-title":"Doxycycline-mediated inhibition of corneal angiogenesis: an MMP-independent mechanism","volume":"54","author":"Su","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2015.09.006_bib0700","doi-asserted-by":"crossref","first-page":"e41858","DOI":"10.1371\/journal.pone.0041858","article-title":"Minocycline inhibits alkali burn-induced corneal neovascularization in mice","volume":"7","author":"Xiao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jfo.2015.09.006_bib0705","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.ophtha.2010.01.037","article-title":"Doxycycline's effect on ocular angiogenesis: an in vivo analysis","volume":"117","author":"Cox","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.09.006_bib0710","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.ico.0000220767.73660.3a","article-title":"The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization","volume":"25","author":"Peyman","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib0715","doi-asserted-by":"crossref","first-page":"9108","DOI":"10.1167\/iovs.11-7255","article-title":"Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects","volume":"52","author":"Su","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2015.09.006_bib0720","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S0161-6420(89)32756-4","article-title":"Topical cyclosporine in high-risk corneal transplants","volume":"96","author":"Belin","year":"1989","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.09.006_bib0725","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1442-9071.2008.01784.x","article-title":"Topical cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial","volume":"36","author":"Poon","year":"2008","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0730","first-page":"529","article-title":"Effects of immunosuppressants after penetrating keratoplasty: meta-analysis of randomized controlled trials","volume":"4","author":"Wei","year":"2011","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0735","doi-asserted-by":"crossref","first-page":"33e1","DOI":"10.1016\/j.ajo.2011.01.019","article-title":"Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation","volume":"152","author":"Shimazaki","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0740","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/ICU.0b013e3282f0ca54","article-title":"Anti-vascular endothelial growth factor therapy for ocular neovascular disease","volume":"18","author":"Andreoli","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0745","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/ICO.0b013e31823f8d71","article-title":"Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study","volume":"31","author":"Benayoun","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib0750","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.jfo.2015.09.006_bib0755","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.jfo.2015.09.006_bib0760","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1006094117427","article-title":"Monoclonal antibodies targeting the VEGF receptor-2 (Flk1\/KDR) as an anti-angiogenic therapeutic strategy","volume":"17","author":"Witte","year":"1998","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jfo.2015.09.006_bib0765","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jfo.2015.09.006_bib0770","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/ICO.0b013e31802b4201","article-title":"Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization","volume":"26","author":"Singh","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib0775","first-page":"99","article-title":"SU5416\u00a0is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types","volume":"59","author":"Fong","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.jfo.2015.09.006_bib0780","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jfo.2015.09.006_bib0785","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL non-inferiority randomized trial","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.09.006_bib0790","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2012.07.058","article-title":"Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology","volume":"119","author":"Ho","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.09.006_bib0795","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib0800","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":"Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0805","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0810","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0815","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0820","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bjophthalmol-2012-302137","article-title":"Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial","volume":"97","author":"Petsoglou","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0825","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.09.006_bib0830","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/ICO.0b013e3181861cc9","article-title":"Bevacizumab (avastin) for corneal neovascularization\u00a0\u2013\u00a0corneal light shield soaked application","volume":"28","author":"Mackenzie","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib0835","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0840","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0845","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","article-title":"Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome","volume":"27","author":"Uy","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib0850","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/ICO.0b013e31817c41e3","article-title":"Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization","volume":"27","author":"Qian","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib0855","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1755-3768.2009.01585.x","article-title":"Subconjunctival bevacizumab for corneal neovascularization","volume":"88","author":"Zaki","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0860","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0865","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.preteyeres.2010.01.002","article-title":"Novel aspects of corneal angiogenic and lymphangiogenic privilege","volume":"29","author":"Ellenberg","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jfo.2015.09.006_bib0870","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":"Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization","volume":"168","author":"Jo","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0875","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1128\/JVI.75.20.9828-9835.2001","article-title":"Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis","volume":"75","author":"Zheng","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0880","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis)","volume":"104","author":"Azar","year":"2006","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.jfo.2015.09.006_bib0885","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","article-title":"Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)","volume":"10","author":"Stevenson","year":"2012","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jfo.2015.09.006_bib0890","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1167\/iovs.11-7871","article-title":"Corneal penetration of topical and subconjunctival bevacizumab","volume":"52","author":"Dastjerdi","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2015.09.006_bib0895","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1389201015666140619120834","article-title":"Quantification, microbial contamination, physico-chemical stability of repackaged bevacizumab stored under different conditions","volume":"15","author":"Signorello","year":"2014","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0900","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharma.2012.03.006","article-title":"Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration","volume":"70","author":"Paul","year":"2012","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.jfo.2015.09.006_bib0905","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2015.09.006_bib0910","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/ICO.0b013e31819839f9","article-title":"Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy","volume":"28","author":"Oh","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib0915","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICO.0b013e3181e291a6","article-title":"Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique","volume":"30","author":"Hashemian","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib0920","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00417-013-2495-0","article-title":"Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes","volume":"252","author":"Moisseiev","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0925","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jfo.2015.09.006_bib0930","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","article-title":"Topical ranibizumab as a treatment of corneal neovascularization","volume":"32","author":"Ferrari","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib0935","first-page":"136","article-title":"Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model","volume":"6","author":"Akar","year":"2013","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0940","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3341\/kjo.2013.27.4.235","article-title":"The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: a preliminary study","volume":"27","author":"Kim","year":"2013","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0945","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/112067211002000106","article-title":"VEGF Trap(R1R2) suppresses experimental corneal angiogenesis","volume":"20","author":"Oliveira","year":"2010","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0950","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/bjo.2008.145128","article-title":"Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation","volume":"93","author":"Bachmann","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0955","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ymthe.2004.09.022","article-title":"Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain","volume":"11","author":"Provost","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.jfo.2015.09.006_bib0960","first-page":"1334","article-title":"Ocular gene therapy: a review of non-viral strategies","volume":"12","author":"Andrieu-Soler","year":"2006","journal-title":"Mol Vis"},{"key":"10.1016\/j.jfo.2015.09.006_bib0965","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/S0002-9440(10)63267-1","article-title":"Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis","volume":"165","author":"Kim","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0970","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/02713681003597230","article-title":"A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization","volume":"35","author":"Zuo","year":"2010","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jfo.2015.09.006_bib0975","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1124\/jpet.108.147496","article-title":"Potent in vivo antiangiogenic effects of GS-101 (5\u2032-TATCCGGAGGGCTCGCCATGCTGCT-3\u2032), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1","volume":"329","author":"Al-Mahmood","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jfo.2015.09.006_bib0980","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1167\/iovs.10-6816","article-title":"Blockade of insulin receptor substrate-1\u00a0inhibits corneal lymphangiogenesis","volume":"52","author":"Hos","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2015.09.006_bib0985","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.ophtha.2014.03.038","article-title":"Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN Study","volume":"121","author":"Cursiefen","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.09.006_bib0990","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2125.2009.03450.x","article-title":"Tolerability and safety of GS-101\u00a0eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a \u2018first in man\u2019 phase I investigation","volume":"68","author":"Kain","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jfo.2015.09.006_bib0995","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1167\/iovs.11-9064","article-title":"Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration","volume":"53","author":"Cloutier","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2015.09.006_bib1000","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jfo.2015.09.006_bib1005","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3\u00a0trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jfo.2015.09.006_bib1010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/archophthalmol.2009.27","article-title":"Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib","volume":"127","author":"Takahashi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib1015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2011.05.016","article-title":"Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats","volume":"666","author":"Yafai","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jfo.2015.09.006_bib1020","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.mvr.2011.09.001","article-title":"Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage","volume":"82","author":"Thakur","year":"2011","journal-title":"Microvasc Res"},{"key":"10.1016\/j.jfo.2015.09.006_bib1025","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1167\/iovs.12-11032","article-title":"Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization","volume":"54","author":"Amparo","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2015.09.006_bib1030","first-page":"595","article-title":"Laser photocoagulation for corneal stromal vascularization","volume":"90","author":"Nirankari","year":"1992","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.jfo.2015.09.006_bib1035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0161-6420(92)31996-7","article-title":"Corneal laser photocoagulation for treatment of neovascularization. Efficacy of 577nm yellow dye laser","volume":"99","author":"Baer","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.09.006_bib1040","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00003226-199405000-00013","article-title":"Hemorrhage complicating YAG laser feeder vessel coagulation of cornea vascularization","volume":"13","author":"Parsa","year":"1994","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib1045","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0161-6420(86)33581-4","article-title":"Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty","volume":"93","author":"Nirankari","year":"1986","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.09.006_bib1050","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/ICO.0b013e318180e50f","article-title":"Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery","volume":"27","author":"Gerten","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib1055","first-page":"50","article-title":"Necrotizing scleritis following laser therapy for corneal vascularization","volume":"41","author":"Pai","year":"2009","journal-title":"Ann Ophthalmol (Skokie)"},{"key":"10.1016\/j.jfo.2015.09.006_bib1060","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/bjo.66.2.127","article-title":"Treatment of lipid keratopathy with the argon laser","volume":"66","author":"Marsh","year":"1982","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib1065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/clm.1996.14.323","article-title":"Vascular effects of photodynamic therapy","volume":"14","author":"Fingar","year":"1996","journal-title":"J Clin Laser Med Surg"},{"key":"10.1016\/j.jfo.2015.09.006_bib1070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00003226-200307000-00018","article-title":"Photodynamic therapy of corneal neovascularization with verteporfin","volume":"22","author":"Fossarello","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib1075","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ajo.2007.05.028","article-title":"Photodynamic therapy with verteporfin for corneal neovascularization","volume":"144","author":"Yoon","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib1080","first-page":"274","article-title":"Treatment of herpes zoster related corneal neovascularisation and lipid keratopathy by photodynamic therapy","volume":"96","author":"Goh","year":"2013","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.jfo.2015.09.006_bib1085","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ajo.2005.11.003","article-title":"Argon laser photodynamic therapy of human corneal neovascularization after intravenous administration of dihematoporphyrin ether","volume":"141","author":"Sheppard","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib1090","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/ICO.0b013e3181b53310","article-title":"Recurrent herpes simplex keratitis after verteporfin photodynamic therapy for corneal neovascularization","volume":"29","author":"Yoon","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib1095","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1001\/archopht.1989.01070020575043","article-title":"Promotion of graft survival by photothrombotic occlusion of corneal neovascularization","volume":"107","author":"Corrent","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib1100","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/bjo.2003.035071","article-title":"Photodynamic therapy for corneal neovascularisation and lipid degeneration","volume":"88","author":"Brooks","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib1105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/ICO.0b013e3181dc81a0","article-title":"Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization","volume":"30","author":"You","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib1110","first-page":"2148","article-title":"Fine needle diathermy occlusion of corneal vessels","volume":"41","author":"Pillai","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2015.09.006_bib1115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.ico.0000248383.09272.ee","article-title":"Electrolysis-needle cauterization of corneal vessels in patients with lipid keratopathy","volume":"26","author":"Wertheim","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib1120","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/ICO.0b013e31823f8f7a","article-title":"Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs","volume":"31","author":"Koenig","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib1125","first-page":"677","article-title":"Epithelial transplantation for the management of severe ocular surface disease","volume":"94","author":"Holland","year":"1996","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.jfo.2015.09.006_bib1130","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0161-6420(89)32833-8","article-title":"Limbal autograft transplantation for ocular surface disorders","volume":"96","author":"Kenyon","year":"1989","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.09.006_bib1135","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0140-6736(96)11188-0","article-title":"Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium","volume":"349","author":"Pellegrini","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jfo.2015.09.006_bib1140","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ophtha.2009.01.005","article-title":"Characterization of the corneal surface in limbal stem cell deficiency and after transplantation of cultivated limbal epithelium","volume":"116","author":"Pauklin","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.09.006_bib1145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/ICO.0b013e31825034be","article-title":"Transplantation of conjunctival epithelial cells cultivated ex vivo in patients with total limbal stem cell deficiency","volume":"32","author":"Ricardo","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.jfo.2015.09.006_bib1150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2012.07.053","article-title":"Visual improvement after cultivated oral mucosal epithelial transplantation","volume":"120","author":"Sotozono","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2015.09.006_bib1155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1542-0124(12)70059-9","article-title":"How does amniotic membrane work?","volume":"2","author":"Tseng","year":"2004","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jfo.2015.09.006_bib1160","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ajo.2008.03.018","article-title":"A systematic literature review of surgical interventions for limbal stem cell deficiency in humans","volume":"146","author":"Cauchi","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2015.09.006_bib1165","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1016\/j.biomaterials.2012.07.029","article-title":"Corneal repair by human corneal keratocyte-reprogrammed iPSCs and amphiphatic carboxymethyl-hexanoyl chitosan hydrogel","volume":"33","author":"Chien","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jfo.2015.09.006_bib0585","doi-asserted-by":"crossref","first-page":"e45435","DOI":"10.1371\/journal.pone.0045435","article-title":"Generation of corneal epithelial cells from induced pluripotent stem cells derived from human dermal fibroblast and corneal limbal epithelium","volume":"7","author":"Hayashi","year":"2012","journal-title":"PLoS One"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551215003320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551215003320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:06:55Z","timestamp":1759259215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551215003320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":117,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0181551215003320"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2015.09.006","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitements actuels de la n\u00e9ovascularisation corn\u00e9enne","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2015.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}